# A Study of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Cancer Patients Undergoing Chemotherapy

> **NCT06706752** · NA · RECRUITING · sponsor: **Sutter Health** · enrollment: 30 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DIETARY_SUPPLEMENT:** Shengbai Oral Formula
- **OTHER:** Inactive Placebo

## Key facts

- **NCT ID:** NCT06706752
- **Lead sponsor:** Sutter Health
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-24
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06706752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06706752, "A Study of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Cancer Patients Undergoing Chemotherapy". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06706752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*